1.11
+0.05(+4.72%)
Currency In USD
| Previous Close | 1.06 |
| Open | 1.07 |
| Day High | 1.13 |
| Day Low | 1.04 |
| 52-Week High | 2.18 |
| 52-Week Low | 0.65 |
| Volume | 556,856 |
| Average Volume | 1.09M |
| Market Cap | 66.22M |
| PE | -0.53 |
| EPS | -2.1 |
| Moving Average 50 Days | 0.98 |
| Moving Average 200 Days | 1.07 |
| Change | 0.05 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $13,875 as of July 10, 2025 at a share price of $1.11. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 0 years ago, it would be worth $860.47 as of July 10, 2025 at a share price of $1.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jul 03, 2025 8:30 PM GMT
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therap
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
GlobeNewswire Inc.
Jun 26, 2025 10:55 AM GMT
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the studyNo evid
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
GlobeNewswire Inc.
Jun 23, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small mole